What is Lexicon Pharmaceuticals, Inc.'s earnings per share (EPS)?

Lexicon Pharmaceuticals, Inc. (LXRX) reported diluted earnings per share of -$0.14 for fiscal year 2025. This represents a 77.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lexicon Pharmaceuticals, Inc. (LXRX) Financials

LXRX

FY2025 annual

Revenue $49.8M +60.2% YoY

Net Income -$50.3M +74.9% YoY

EPS (Diluted) -$0.14 +77.8% YoY

Free Cash Flow -$67.9M +62.3% YoY

Market Cap $889.9M as of Sep 11, 2026

Price / Sales 21.5x on $41.5M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 5.1x on $174.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LXRX SEC filings page.

Lexicon Pharmaceuticals, Inc. (LXRX) reported $49.8M in revenue for fiscal year 2025, up 60.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LXRX FY2025 2026-08-30

Lexicon’s development-stage model is shifting toward revenue, while expense compression—not capex—drives the change in cash economics.

Operating loss narrowed to $48.9M in FY2025 while revenue reached $49.8M, showing commercial growth now sits alongside a much smaller cost base. SG&A fell to $37.3M while R&D remained $61.1M, so the improvement reflects a broad expense reset with development spending still larger than reported revenue—not simply scale flowing through the income statement.

With capex at $0, free cash flow matched operating cash flow at -$67.9M, tying the outflow to ongoing operations rather than physical reinvestment. The business is therefore consuming cash primarily to fund its operating and development platform, not to build a heavy asset base.

The reported liquidity comparison was 17 months, while the current ratio remained 4.9x, indicating substantial short-term coverage relative to current liabilities at year-end. Debt-to-equity also declined to 0.5x from 0.7x in FY2024, so leverage eased even while internal cash generation remained negative.

Financial Health Signals

Financial Health Score 64/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Lexicon Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Lexicon Pharmaceuticals, Inc. held $96.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $67.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Lexicon Pharmaceuticals, Inc. scores 41/100 among other emerging companies.

Dilution

Lexicon Pharmaceuticals, Inc. had 424M shares outstanding at the end of fiscal year 2025, against 361M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Lexicon Pharmaceuticals, Inc. scores 25/100 among other emerging companies.

R&D Intensity

Lexicon Pharmaceuticals, Inc. spent $61.1M on research and development in fiscal year 2025, which was 61.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Lexicon Pharmaceuticals, Inc. scores 85/100 among other emerging companies.

Revenue Progress

Lexicon Pharmaceuticals, Inc. reported revenue of $49.8M in fiscal year 2025, against $31.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Lexicon Pharmaceuticals, Inc. scores 96/100 among other emerging companies.

Burn Trend

Lexicon Pharmaceuticals, Inc.'s operations used $67.9M of cash in fiscal year 2025, against $178.8M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Lexicon Pharmaceuticals, Inc. scores 74/100 among other emerging companies.

Balance Sheet

Lexicon Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $96.2M at the end of fiscal year 2025, against $77.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Lexicon Pharmaceuticals, Inc. scores 64/100 among other emerging companies.

Altman Z-Score Distress

-8.45

Lexicon Pharmaceuticals, Inc. scores -8.45, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($889.9M) relative to total liabilities ($77.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

Lexicon Pharmaceuticals, Inc. passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Lexicon Pharmaceuticals, Inc. reported a net loss of $50.3M while operations used $67.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$692K

YoY-97.6%

QoQ-96.7%

Lexicon Pharmaceuticals, Inc. generated $692K in revenue in Q2 2026. This represents a decrease of 97.6% from the same quarter a year earlier. Against the prior quarter it is down 96.7%.

EBITDA

-$26.4M

YoY-775.8%

QoQ-2884.0%

Lexicon Pharmaceuticals, Inc.'s EBITDA was -$26.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 775.8% from the same quarter a year earlier. Against the prior quarter it is down 2884.0%.

Net Income

-$31.8M

YoY-1077.1%

QoQ-2946.5%

Lexicon Pharmaceuticals, Inc. reported -$31.8M in net income in Q2 2026. This represents a decrease of 1077.1% from the same quarter a year earlier. Against the prior quarter it is down 2946.5%.

EPS (Diluted)

-$0.07

YoY-800.0%

Lexicon Pharmaceuticals, Inc. earned -$0.07 per diluted share (EPS) in Q2 2026. This represents a decrease of 800.0% from the same quarter a year earlier.

Cash & Balance Sheet

Cash & Debt

$40.9M

YoY+91.6%

QoQ+7.4%

5Y CAGR-14.6%

10Y CAGR+0.6%

Lexicon Pharmaceuticals, Inc. held $40.9M in cash against $51.4M in long-term debt as of Q2 2026.

Shares Outstanding

445M

YoY+22.4%

QoQ+0.2%

Lexicon Pharmaceuticals, Inc. had 445M shares outstanding in Q2 2026. This represents an increase of 22.4% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

94.4%

YoY-5.5pp

QoQ-5.1pp

Lexicon Pharmaceuticals, Inc.'s gross margin was 94.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 5.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.1 percentage points.

Return on Equity

-18.2%

YoY-20.7pp

QoQ-17.7pp

Lexicon Pharmaceuticals, Inc.'s ROE was -18.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 20.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 17.7 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$17.4M

YoY+10.8%

QoQ+36.7%

Lexicon Pharmaceuticals, Inc. invested $17.4M in research and development in Q2 2026. This represents an increase of 10.8% from the same quarter a year earlier. Against the prior quarter it is up 36.7%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

LXRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LXRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$41.5M	$49.8M+60.2%	$31.1M+2481.5%	$1.2M+766.2%	$139K-53.4%	$298K-98.8%	$24.0M-92.5%	$322.1M+409.5%	$63.2M-31.1%	$91.7M+15.7%	$79.3M-39.0%	$130.0M+468.9%	$22.9M+928.5%	$2.2M+104.0%	$1.1M-41.1%	$1.8M
Cost of Revenue	$358K	$274K-55.5%	$616K+624.7%	$85K	$0	$0-100.0%	$1.9M-40.3%	$3.2M+29.7%	$2.5M+31.2%	$1.9M	$0	$0	N/A	N/A	N/A	N/A
Gross Profit	$41.1M	$49.5M+62.6%	$30.5M+2622.5%	$1.1M+705.0%	$139K-53.4%	$298K-98.6%	$22.1M-93.1%	$318.8M+425.1%	$60.7M-32.4%	$89.8M+13.3%	$79.3M-39.0%	$130.0M	N/A	N/A	N/A	N/A
R&D Expenses	$60.3M	$61.1M-27.7%	$84.5M+43.5%	$58.9M+11.5%	$52.8M-4.1%	$55.0M-64.2%	$153.6M+67.1%	$91.9M-8.3%	$100.2M-34.1%	$152.2M-7.2%	$164.0M+72.3%	$95.2M+6.6%	$89.3M-0.4%	$89.7M+8.6%	$82.6M-10.1%	$91.8M
SG&A Expenses	$35.3M	$37.3M-73.9%	$143.1M+25.5%	$114.0M+137.1%	$48.1M+48.7%	$32.3M-31.5%	$47.2M-16.9%	$56.8M-10.9%	$63.8M-3.5%	$66.1M+53.1%	$43.2M+81.1%	$23.8M+22.8%	$19.4M+13.4%	$17.1M+0.5%	$17.0M-1.8%	$17.4M
Operating Income	-$54.5M	-$48.9M+75.2%	-$197.1M-14.8%	-$171.8M-70.5%	-$100.8M-15.7%	-$87.1M-82.2%	-$47.8M-133.8%	$141.4M+237.0%	-$103.3M+20.9%	-$130.6M-2.7%	-$127.2M-8762.9%	$1.5M+101.5%	-$100.4M+2.0%	-$102.4M+5.6%	-$108.4M+5.0%	-$114.1M
EBITDA	N/A	-$48.3M+75.4%	-$196.6M-14.8%	-$171.2M-70.6%	-$100.3M-15.6%	-$86.8M-93.5%	-$44.9M-130.9%	$145.1M+245.7%	-$99.6M+21.7%	-$127.2M-1.7%	-$125.1M-5800.0%	$2.2M+102.2%	-$98.4M+1.1%	-$99.5M+4.5%	-$104.2M+4.6%	-$109.2M
Interest Expense	N/A	N/A	N/A	N/A	$2.8M+246.6%	$802K-94.5%	$14.5M-29.7%	$20.7M-0.5%	$20.8M+197.5%	$7.0M+6.3%	$6.6M-2.3%	$6.7M+198.4%	$2.3M+14.3%	$2.0M-6.8%	$2.1M-16.4%	$2.5M
Income Tax	N/A	N/A	$0	$0	$0	$0	N/A	N/A	N/A	N/A	$0	$0+100.0%	-$70K	$0	$0	$0
Net Income	-$61.1M	-$50.3M+74.9%	-$200.4M-13.1%	-$177.1M-73.7%	-$101.9M-16.2%	-$87.8M-49.8%	-$58.6M-145.0%	$130.1M+208.0%	-$120.5M+2.0%	-$123.0M+6.4%	-$131.4M-2707.5%	-$4.7M+95.3%	-$100.3M+3.7%	-$104.1M+5.5%	-$110.2M+5.2%	-$116.2M
EPS (Basic)	N/A	-$0.14+77.8%	-$0.63+21.3%	-$0.80-29.0%	-$0.62-3.3%	-$0.60-13.2%	-$0.53-143.1%	$1.23+207.9%	-$1.14+2.6%	-$1.17	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.15	-$0.14+77.8%	-$0.63+21.3%	-$0.80-29.0%	-$0.62-3.3%	-$0.60-13.2%	-$0.53-145.7%	$1.16+201.8%	-$1.14+2.6%	-$1.17	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	363M+13.4%	320M+44.7%	221M+33.4%	166M+13.8%	146M+31.4%	111M-5.1%	117M+10.3%	106M+0.6%	105M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$692K-97.6%	$21.1M+1572.1%	$5.5M-79.3%	$14.2M+710.4%	$28.9M+1652.6%	$1.3M+11.7%	$26.6M+3688.0%	$1.8M+980.2%
Cost of Revenue	$39K+18.2%	$108K+260.0%	$201K-42.2%	$10K-85.9%	$33K-80.1%	$30K-3.2%	$348K+397.1%	$71K+914.3%
Gross Profit	$653K-97.7%	$21.0M+1604.1%	$5.3M-79.8%	$14.2M+744.1%	$28.8M+1846.9%	$1.2M+12.1%	$26.2M+4053.1%	$1.7M+983.2%
R&D Expenses	$17.4M+10.8%	$12.8M-16.6%	$11.3M-57.6%	$18.8M-27.2%	$15.7M-10.7%	$15.3M+6.5%	$26.7M+80.8%	$25.8M+46.8%
SG&A Expenses	$9.8M+4.3%	$9.2M-20.5%	$8.8M-72.8%	$7.6M-80.8%	$9.3M-76.1%	$11.6M-63.8%	$32.3M-1.1%	$39.6M+22.8%
Operating Income	-$26.5M-810.4%	-$996K+96.1%	-$14.8M+54.8%	-$12.2M+80.9%	$3.7M+106.7%	-$25.7M+43.4%	-$32.7M+30.0%	-$63.7M-28.3%
EBITDA	-$26.4M-775.8%	-$886K+96.5%	-$14.7M+55.0%	-$12.0M+81.1%	$3.9M+107.1%	-$25.5M+43.6%	-$32.6M+30.0%	-$63.6M-28.5%
Net Income	-$31.8M-1077.1%	-$1.0M+95.9%	-$15.5M+54.0%	-$12.8M+80.3%	$3.3M+106.1%	-$25.3M+47.7%	-$33.8M+32.1%	-$64.8M-28.3%
EPS (Basic)	-$0.07-800.0%	$0.00+100.0%	-$0.04+55.6%	-$0.04+77.8%	$0.01+105.9%	-$0.07+65.0%	-$0.09+55.0%	-$0.18+14.3%
EPS (Diluted)	-$0.07-800.0%	$0.00+100.0%	-$0.04+55.6%	-$0.04+77.8%	$0.01+105.9%	-$0.07+65.0%	-$0.09	-$0.18+14.3%
Diluted Shares (Avg)	438M+20.4%	400M+10.5%	N/A	363M+0.5%	364M+17.0%	362M+47.6%	N/A	361M+47.6%

Not reported in any period shown, so not listed: Interest Expense, Income Tax.

LXRX Balance Sheet

LXRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$185.0M-38.0%	$298.4M+30.1%	$229.4M+18.1%	$194.3M+41.9%	$136.9M-32.8%	$203.8M-51.2%	$417.7M+47.0%	$284.1M-34.9%	$436.5M-8.2%	$475.6M-27.0%	$652.0M+38.3%	$471.4M+71.9%	$274.2M-26.3%	$371.8M-13.6%	$430.5M
Current Assets	$101.9M-58.6%	$246.2M+39.4%	$176.5M+25.3%	$140.9M+58.4%	$88.9M-43.6%	$157.7M-53.3%	$337.8M+94.9%	$173.3M-46.2%	$322.0M-10.0%	$357.9M-32.8%	$532.4M+44.3%	$369.0M+174.2%	$134.6M-41.7%	$230.9M-19.2%	$285.8M
Cash & Equivalents	$34.3M-48.5%	$66.7M+196.7%	$22.5M-51.5%	$46.3M-27.7%	$64.1M-49.3%	$126.3M+249.6%	$36.1M-55.1%	$80.4M+30.4%	$61.7M+32.3%	$46.6M-77.0%	$203.0M+47.9%	$137.3M+266.1%	$37.5M+23.3%	$30.4M-83.7%	$186.3M
Short-Term Investments	$61.9M-63.9%	$171.3M+16.1%	$147.6M+60.4%	$92.0M+305.7%	$22.7M-12.8%	$26.0M-89.0%	$235.5M+195.7%	$79.7M-68.0%	$249.1M-16.9%	$299.9M-5.8%	$318.4M+57.5%	$202.1M+120.5%	$91.6M-52.5%	$192.8M+102.1%	$95.4M
Inventory	$281K+21.6%	$231K-39.4%	$381K	$0	N/A	$0-100.0%	$4.2M-9.3%	$4.7M+140.2%	$1.9M	$0	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.4M-31.4%	$3.5M+243.9%	$1.0M+3507.1%	$28K+100.0%	$14K-96.5%	$395K-99.3%	$56.5M+854.3%	$5.9M+22.8%	$4.8M-35.6%	$7.5M+722.4%	$911K-12.0%	$1.0M+31.0%	$790K-42.7%	$1.4M+293.7%	$350K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M
Total Liabilities	$77.4M-49.2%	$152.5M+11.8%	$136.3M+76.6%	$77.2M+231.0%	$23.3M-50.8%	$47.4M-84.2%	$300.6M-3.2%	$310.5M-15.7%	$368.3M+15.7%	$318.2M-13.1%	$366.1M+95.4%	$187.4M+80.2%	$104.0M-1.0%	$105.1M-20.9%	$132.9M
Current Liabilities	$20.9M-53.9%	$45.2M+43.4%	$31.5M+36.1%	$23.2M+4.7%	$22.1M-52.7%	$46.8M-28.4%	$65.3M+77.8%	$36.8M-65.2%	$105.5M-35.9%	$164.6M+33.9%	$123.0M+173.4%	$45.0M+133.1%	$19.3M+5.5%	$18.3M-14.5%	$21.4M
Non-Current Liabilities	$56.6M-47.2%	$107.2M+2.3%	$104.8M+94.0%	$54.0M+4438.1%	$1.2M+94.8%	$611K-99.7%	$235.3M-14.1%	$273.8M+4.2%	$262.8M+71.1%	$153.6M-36.8%	$243.2M+70.8%	$142.4M+68.1%	$84.7M-2.4%	$86.8M-22.2%	$111.6M
Long-Term Debt	$49.4M-50.7%	$100.3M+0.8%	$99.5M+104.8%	$48.6M	$0	$0-100.0%	$234.2M-4.0%	$243.9M+5.3%	$231.6M+171.9%	$85.2M-15.6%	$101.0M+15.4%	$87.5M+333.9%	$20.2M-7.8%	$21.9M-6.7%	$23.5M
Total Equity	$107.5M-26.3%	$145.9M+56.8%	$93.1M-20.5%	$117.1M+3.1%	$113.6M-27.4%	$156.4M+33.5%	$117.1M+543.5%	-$26.4M-138.7%	$68.3M-59.2%	$167.5M-41.4%	$286.0M+0.7%	$284.0M+66.9%	$170.2M-36.2%	$266.7M-10.4%	$297.6M
Retained Earnings	-$2.0B-2.6%	-$2.0B-11.3%	-$1.8B-11.1%	-$1.6B-6.9%	-$1.5B-6.3%	-$1.4B-4.4%	-$1.3B+8.8%	-$1.5B-7.8%	-$1.4B-9.2%	-$1.3B-12.8%	-$1.1B-0.4%	-$1.1B-10.0%	-$1.0B-11.6%	-$899.8M-14.0%	-$789.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$250.1M+10.9%	$268.8M-9.7%	$185.0M-38.0%	$205.9M-35.9%	$225.6M-39.6%	$297.7M-28.7%	$298.4M+30.1%	$321.1M+16.1%
Current Assets	$196.6M+35.5%	$186.0M-24.3%	$101.9M-58.6%	$122.5M-54.4%	$145.1M-54.8%	$245.8M-32.6%	$246.2M+39.4%	$268.6M+20.3%
Cash & Equivalents	$40.9M+91.6%	$38.1M-39.4%	$34.3M-48.5%	$49.7M+43.7%	$21.4M-40.0%	$62.9M-34.8%	$66.7M+196.7%	$34.6M+63.6%
Short-Term Investments	$149.7M+27.2%	$132.6M+0.5%	$61.9M-63.9%	$66.3M-70.4%	$117.6M-57.1%	$132.0M-49.1%	$171.3M+16.1%	$223.8M+13.4%
Inventory	$1.2M+611.9%	$276K+37.3%	$281K+21.6%	$158K-75.2%	$168K-71.3%	$201K-60.9%	$231K-39.4%	$636K+89.3%
Accounts Receivable	$1.6M-24.7%	$11.8M-75.2%	$2.4M-31.4%	$2.3M-19.4%	$2.2M-16.7%	$47.4M+3009.2%	$3.5M+243.9%	$2.9M+810.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%
Total Liabilities	$75.5M-21.4%	$66.0M-62.2%	$77.4M-49.2%	$85.8M-39.9%	$96.1M-27.9%	$174.6M+36.1%	$152.5M+11.8%	$142.6M+4.1%
Current Liabilities	$14.7M-57.8%	$9.9M-91.1%	$20.9M-53.9%	$21.7M-39.7%	$34.8M+25.0%	$110.7M+373.1%	$45.2M+43.4%	$36.0M+11.7%
Non-Current Liabilities	$60.8M-0.8%	$56.1M-12.3%	$56.6M-47.2%	$64.0M-39.9%	$61.3M-41.9%	$63.9M-39.1%	$107.2M+2.3%	$106.6M+1.8%
Long-Term Debt	$51.4M-8.3%	$49.7M-15.3%	$49.4M-50.7%	$56.5M-43.4%	$56.1M-43.6%	$58.6M-41.3%	$100.3M+0.8%	$99.9M+0.6%
Total Equity	$174.5M+34.8%	$202.9M+64.9%	$107.5M-26.3%	$120.2M-32.7%	$129.4M-46.1%	$123.0M-57.4%	$145.9M+56.8%	$178.5M+28.0%
Retained Earnings	-$2.1B-3.1%	-$2.0B-1.3%	-$2.0B-2.6%	-$2.0B-3.5%	-$2.0B-6.5%	-$2.0B-9.8%	-$2.0B-11.3%	-$1.9B-12.6%

LXRX Cash Flow Statement

LXRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$65.0M	-$67.9M+62.0%	-$178.8M-10.4%	-$161.9M-82.2%	-$88.9M-2.1%	-$87.0M+39.1%	-$143.0M-225.6%	$113.8M+176.6%	-$148.6M+19.8%	-$185.4M-5.6%	-$175.6M-195.0%	$184.8M+344.3%	-$75.6M+17.0%	-$91.1M+3.6%	-$94.5M-7.4%	-$87.9M
Depreciation & Amortization	N/A	$621K+16.3%	$534K-3.6%	$554K+29.7%	$427K+46.2%	$292K-90.0%	$2.9M-19.7%	$3.7M-0.8%	$3.7M+8.4%	$3.4M+65.3%	$2.1M+182.8%	$727K-62.3%	$1.9M-32.7%	$2.9M-31.7%	$4.2M-14.3%	$4.9M
Stock-Based Compensation	N/A	$12.5M-7.3%	$13.5M-5.9%	$14.3M+24.5%	$11.5M+8.9%	$10.6M-20.3%	$13.3M-6.6%	$14.2M+21.6%	$11.7M+23.5%	$9.5M+27.1%	$7.5M+8.9%	$6.8M-3.4%	$7.1M-4.6%	$7.4M+14.3%	$6.5M+13.8%	$5.7M
Capital Expenditures	N/A	$0-100.0%	$1.0M+119.4%	$470K-64.6%	$1.3M+8.6%	$1.2M+1303.4%	$87K+24.3%	$70K-26.3%	$95K-58.3%	$228K-1.3%	$231K-74.6%	$910K+1037.5%	$80K-95.4%	$1.7M+249.8%	$492K-59.2%	$1.2M
Free Cash Flow	N/A	-$67.9M+62.3%	-$179.8M-10.7%	-$162.4M-80.1%	-$90.2M-2.2%	-$88.2M+38.3%	-$143.1M-225.8%	$113.7M+176.5%	-$148.7M+19.9%	-$185.6M-5.6%	-$175.9M-195.6%	$183.9M+342.9%	-$75.7M+18.4%	-$92.8M+2.3%	-$95.0M-6.5%	-$89.1M
Investing Cash Flow	-$29.8M	$113.0M+834.9%	-$15.4M+69.2%	-$49.9M+29.7%	-$71.1M-3468.6%	$2.1M-99.4%	$380.8M+344.3%	-$155.9M-191.9%	$169.6M+235.6%	$50.5M+176.8%	$18.3M+115.6%	-$117.0M-7.9%	-$108.4M-208.9%	$99.5M+201.8%	-$97.8M-239.8%	$70.0M
Financing Cash Flow	$85.3M	-$48.5M-120.3%	$238.3M+26.8%	$188.0M+32.2%	$142.2M+526.2%	$22.7M+115.4%	-$147.6M-6532.3%	-$2.2M+0.8%	-$2.2M-101.5%	$149.9M+15090.8%	$987K+148.6%	-$2.0M-100.7%	$283.8M+20532.5%	-$1.4M-103.8%	$36.4M-76.8%	$157.1M
Share Buybacks	N/A	N/A	$1.7M+110.0%	$824K-4.6%	$864K-67.7%	$2.7M+160.7%	$1.0M+9.0%	$941K-3.2%	$972K-42.1%	$1.7M+170.4%	$621K+73.9%	$357K-59.8%	$887K+1.6%	$873K+206.3%	$285K+163.9%	$108K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$9.2M-154.1%	-$14.7M+66.4%	-$17.2M+19.8%	-$23.8M+55.6%	$17.0M+135.0%	-$43.8M+20.6%	-$21.5M+57.5%	-$53.6M-28.8%
Depreciation & Amortization	$102K-42.0%	$110K-37.5%	$118K-5.6%	$151K+19.8%	$176K+26.6%	$176K+22.2%	$125K-15.0%	$126K-16.6%
Stock-Based Compensation	$3.3M+3.1%	$3.1M+1.2%	N/A	$3.4M+21.4%	$3.2M-34.7%	$3.0M-29.3%	N/A	$2.8M-28.2%
Capital Expenditures	N/A	N/A	$0-100.0%	$0-100.0%	N/A	N/A	$474K	$307K+269.9%
Free Cash Flow	N/A	N/A	-$17.2M+21.5%	-$23.8M+55.8%	N/A	N/A	-$22.0M+56.5%	-$53.9M-29.3%
Investing Cash Flow	-$16.5M-206.3%	-$70.3M-273.1%	$4.8M-91.0%	$52.1M-2.5%	$15.5M+225.6%	$40.6M+136.8%	$53.7M+3.5%	$53.5M+236.0%
Financing Cash Flow	-$512K+98.9%	$88.8M+15616.8%	-$2.9M-2714.4%	$0+100.0%	-$45.0M-321328.6%	-$572K-100.2%	-$104K-10300.0%	-$916K-336.2%
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0

Not reported in any period shown, so not listed: Dividends Paid.

LXRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LXRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	99.5%+1.4pp	98.0%+5.1pp	92.9%-7.1pp	100.0%0.0pp	100.0%+8.0pp	92.0%-7.0pp	99.0%+2.9pp	96.1%-1.9pp	97.9%-2.1pp	100.0%0.0pp	100.0%	N/A	N/A	N/A	N/A
Operating Margin	-98.2%	-634.2%	-14264.9%	-72489.2%	-29224.8%	-199.2%	43.9%	-163.4%	-142.5%	-160.5%	1.1%	-439.2%	-4607.2%	-9955.5%	-6170.6%
Net Margin	-101.1%	-644.8%	-14710.9%	-73341.0%	-29449.0%	-244.1%	40.4%	-190.7%	-134.1%	-165.9%	-3.6%	-438.8%	-4686.1%	-10120.4%	-6285.3%
Return on Equity	-46.8%+90.5pp	-137.3%+52.9pp	-190.2%-103.2pp	-87.0%-9.8pp	-77.3%-39.8pp	-37.5%-148.6pp	111.1%	N/A	-180.2%-101.7pp	-78.5%-76.8pp	-1.6%+33.7pp	-35.3%+25.9pp	-61.2%-19.9pp	-41.3%-2.3pp	-39.1%
Return on Assets	-27.2%+39.9pp	-67.2%+10.1pp	-77.2%-24.7pp	-52.5%+11.6pp	-64.1%-35.4pp	-28.7%-59.9pp	31.1%+73.6pp	-42.4%-14.3pp	-28.2%-0.5pp	-27.6%-26.9pp	-0.7%+20.6pp	-21.3%+16.7pp	-38.0%-8.3pp	-29.6%-2.7pp	-27.0%
Current Ratio	4.88-0.6x	5.44-0.2x	5.60-0.5x	6.08+2.1x	4.02+0.6x	3.37-1.8x	5.17+0.5x	4.72+1.7x	3.05+0.9x	2.17-2.2x	4.33-3.9x	8.21+1.2x	6.97-5.7x	12.63-0.7x	13.36
Debt-to-Equity	0.46-0.2x	0.69-0.4x	1.07+0.7x	0.41+0.4x	0.000.0x	0.00-2.0x	2.00	N/A	3.39+2.9x	0.51+0.2x	0.350.0x	0.31+0.2x	0.120.0x	0.080.0x	0.08
Asset Turnover	0.27+0.2x	0.10+0.1x	0.010.0x	0.000.0x	0.00-0.1x	0.12-0.7x	0.77+0.5x	0.220.0x	0.210.0x	0.170.0x	0.20+0.2x	0.050.0x	0.010.0x	0.000.0x	0.00
FCF Margin	-136.2%	-578.5%	-13485.6%	-64875.5%	-29610.1%	-596.2%	35.3%	-235.3%	-202.5%	-221.9%	141.4%	-331.2%	-4176.4%	-8719.2%	-4821.2%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	94.4%-5.5pp	99.5%+1.9pp	96.3%-2.3pp	99.9%+4.0pp	99.9%+10.0pp	97.6%+0.4pp	98.7%+8.7pp	95.9%+0.3pp
Operating Margin	-3835.3%	-4.7%	-269.1%	-85.9%	12.9%	-2034.8%	-123.3%	-3639.6%
Net Margin	-4591.8%	-4.9%	-282.7%	-90.0%	11.3%	-2004.4%	-127.2%	-3703.5%
Return on Equity	-18.2%-20.7pp	-0.5%+20.1pp	-14.4%+8.7pp	-10.6%+25.7pp	2.5%+24.8pp	-20.6%-3.8pp	-23.1%+30.3pp	-36.3%-0.1pp
Return on Assets	-12.7%-14.1pp	-0.4%+8.1pp	-8.4%+2.9pp	-6.2%+14.0pp	1.4%+15.8pp	-8.5%+3.1pp	-11.3%+10.4pp	-20.2%-1.9pp
Current Ratio	13.37+9.2x	18.79+16.6x	4.88-0.6x	5.64-1.8x	4.16-7.3x	2.22-13.4x	5.44-0.2x	7.45+0.5x
Debt-to-Equity	0.29-0.1x	0.24-0.2x	0.46-0.2x	0.47-0.1x	0.430.0x	0.48+0.1x	0.69-0.4x	0.56-0.2x
Asset Turnover	0.00-0.1x	0.08+0.1x	0.03-0.1x	0.07+0.1x	0.13+0.1x	0.000.0x	0.09+0.1x	0.010.0x
FCF Margin	N/A	N/A	-313.7%	-168.1%	N/A	N/A	-82.7%	-3081.5%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Lexicon Pharmaceuticals, Inc. LXRX	FY2025	$49.8M	-$50.3M	N/A	$889.9M	64/100
Aura Biosciences, Inc. AURA	FY2025	N/A	-$106.2M	N/A	$724.9M	—
Fulcrum Therapeutics FULC	FY2025	$0	-$74.9M	N/A	$289.9M	—
Astria Therapeutics Inc ATXS	FY2024	N/A	-$94.3M	N/A	$718.1M	—
Solid Bioscience SLDB	FY2025	N/A	-$174.3M	N/A	$972.5M	—
Inhibrx Biosciences Inc INBX	FY2025	$1.3M	-$140.1M	N/A	$1.6B	21/100

Where Lexicon Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is Lexicon Pharmaceuticals, Inc.'s annual revenue?

Lexicon Pharmaceuticals, Inc. (LXRX) reported $49.8M in total revenue for fiscal year 2025. This represents a 60.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lexicon Pharmaceuticals, Inc.'s revenue growing?

Lexicon Pharmaceuticals, Inc. (LXRX) revenue grew by 60.2% year-over-year, from $31.1M to $49.8M in fiscal year 2025.

Is Lexicon Pharmaceuticals, Inc. profitable?

No, Lexicon Pharmaceuticals, Inc. (LXRX) reported a net income of -$50.3M in fiscal year 2025.

What is Lexicon Pharmaceuticals, Inc.'s EBITDA?

Lexicon Pharmaceuticals, Inc. (LXRX) had EBITDA of -$48.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Lexicon Pharmaceuticals, Inc. have?

As of fiscal year 2025, Lexicon Pharmaceuticals, Inc. (LXRX) had $34.3M in cash and equivalents against $49.4M in long-term debt.

What is Lexicon Pharmaceuticals, Inc.'s gross margin?

Lexicon Pharmaceuticals, Inc. (LXRX) had a gross margin of 99.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lexicon Pharmaceuticals, Inc.'s operating margin?

Lexicon Pharmaceuticals, Inc. (LXRX) had an operating margin of -98.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Lexicon Pharmaceuticals, Inc.'s return on equity (ROE)?

Lexicon Pharmaceuticals, Inc. (LXRX) has a return on equity of -46.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lexicon Pharmaceuticals, Inc.'s free cash flow?

Lexicon Pharmaceuticals, Inc. (LXRX) recorded an outflow of $67.9M in free cash flow during fiscal year 2025. This represents a 62.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lexicon Pharmaceuticals, Inc.'s operating cash flow?

Lexicon Pharmaceuticals, Inc. (LXRX) recorded an outflow of $67.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Lexicon Pharmaceuticals, Inc.'s total assets?

Lexicon Pharmaceuticals, Inc. (LXRX) had $185.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lexicon Pharmaceuticals, Inc.'s capital expenditures?

Lexicon Pharmaceuticals, Inc. (LXRX) reported no capital expenditure during fiscal year 2025.

How much does Lexicon Pharmaceuticals, Inc. spend on research and development?

Lexicon Pharmaceuticals, Inc. (LXRX) invested $61.1M in research and development during fiscal year 2025.

How many shares does Lexicon Pharmaceuticals, Inc. have outstanding?

Lexicon Pharmaceuticals, Inc. (LXRX) had 424M shares outstanding as of fiscal year 2025.

What is Lexicon Pharmaceuticals, Inc.'s current ratio?

Lexicon Pharmaceuticals, Inc. (LXRX) had a current ratio of 4.88 as of fiscal year 2025, which is generally considered healthy.

What is Lexicon Pharmaceuticals, Inc.'s debt-to-equity ratio?

Lexicon Pharmaceuticals, Inc. (LXRX) had a debt-to-equity ratio of 0.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lexicon Pharmaceuticals, Inc.'s return on assets (ROA)?

Lexicon Pharmaceuticals, Inc. (LXRX) had a return on assets of -27.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lexicon Pharmaceuticals, Inc.'s P/E ratio?

Lexicon Pharmaceuticals, Inc. (LXRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $889.9M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Lexicon Pharmaceuticals, Inc.'s price-to-sales ratio?

Lexicon Pharmaceuticals, Inc. (LXRX) trades at 21.5x sales, its market capitalization divided by revenue of $41.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $889.9M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Lexicon Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Lexicon Pharmaceuticals, Inc. (LXRX) held $96.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $67.9M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Lexicon Pharmaceuticals, Inc.'s Altman Z-Score?

Lexicon Pharmaceuticals, Inc. (LXRX) has an Altman Z-Score of -8.45, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Lexicon Pharmaceuticals, Inc.'s Piotroski F-Score?

Lexicon Pharmaceuticals, Inc. (LXRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lexicon Pharmaceuticals, Inc.'s earnings high quality?

Lexicon Pharmaceuticals, Inc. (LXRX) reported a net loss of $50.3M while operations used $67.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Lexicon Pharmaceuticals, Inc.?

Lexicon Pharmaceuticals, Inc. (LXRX) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.